- Home
- LXRX
as 04-18-2025 1:39pm EST
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | THE WOODLANDS |
| Market Cap: | 124.4M | IPO Year: | 2000 |
| Target Price: | $3.67 | AVG Volume (30 days): | 32.2M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.28 - $2.45 | Next Earning Date: | 05-01-2025 |
| Revenue: | $31,081,000 | Revenue Growth: | 2481.48% |
| Revenue Growth (this year): | -69.35% | Revenue Growth (next year): | 63.36% |
Latest Lexicon Pharmaceuticals Inc. News
LXRX Breaking Stock News: Dive into LXRX Ticker-Specific Updates for Smart Investing
Zacks
17 days ago
LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?
GlobeNewswire
17 days ago
Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
MT Newswires
18 days ago
Social Buzz: Wallstreetbets Stocks Mixed Premarket Tuesday; Tesla to Advance, Lexicon Pharmaceuticals to Decline
Investor's Business Daily
22 days ago
Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1
MT Newswires
22 days ago
Top Midday Gainers
Pharmaceutical Technology
22 days ago
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
MT Newswires
22 days ago
Sector Update: Health Care Stocks Steady Premarket Friday
MT Newswires
22 days ago
Lexicon Pharmaceuticals Enters License Agreement With Novo Nordisk for Obesity Drug; Shares Jump
Compare LXRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LXRX Lexicon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.